• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Directories » FDA Approved Drugs » Turalio (pexidartinib)

AND
  • A
  • B
  • C
  • D
  • E
  • F
  • G
  • H
  • I
  • J
  • K
  • L
  • M
  • N
  • O
  • P
  • Q
  • R
  • S
  • T
  • U
  • V
  • W
  • X
  • Y
  • Z

Turalio (pexidartinib)

  • Profile

Profile

Contact Information

Contact: Daiichi Sankyo
Website: www.turalio.com

Currently Enrolling Trials

    Show More

    General Information

    Turalio (pexidartinib) is a kinase inhibitor.

    Turalio is specifically indicated for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) associated with severe morbidity or functional limitations and not amenable to improvement with surgery. 

    Turalio is supplied as a capsule for oral administration. Turalio should be administered on an empty stomach, at least one hour before or two hours after a meal or snack. The recommended dosage of Turalio is 400 mg taken twice daily on an empty stomach until disease progression or unacceptable toxicity. Turalio capsules should be swallowed whole. Do not open, break, or chew the capsules. If a patient vomits or misses a dose of Turalio, instruct the patient to take the next dose at its scheduled time. 

    Please see drug label for specific dose modifications.

    Mechanism of Action

    Turalio (pexidartinib) is a small molecule tyrosine kinase inhibitor that targets colony stimulating factor 1 receptor (CSF1R), KIT proto-oncogene receptor tyrosine kinase (KIT), and FMS-like tyrosine kinase 3 (FLT3) harboring an internal tandem duplication (ITD) mutation. Overexpression of the CSF1R ligand promotes cell proliferation and accumulation in the synovium. In vitro, pexidartinib inhibited proliferation of cell lines dependent on CSF1R and ligand-induced autophosphorylation of CSF1R. Pexidartinib also inhibited the proliferation of a CSF1R dependent cell line in vivo. 

    Side Effects

    Adverse effects associated with the use of Turalio may include, but are not limited to, the following:

    • increased lactate dehydrogenase
    • increased aspartate aminotransferase
    • hair color changes
    • fatigue
    • increased alanine aminotransferase
    • decreased neutrophils
    • increased cholesterol
    • increased alkaline phosphatase
    • decreased lymphocytes
    • eye edema
    • decreased hemoglobin
    • rash
    • dysgeusia
    • decreased phosphate

    The Turalio drug label comes with the following Black Box Warning: HEPATOTOXICITY • Turalio can cause serious and potentially fatal liver injury. Monitor liver tests prior to initiation of Turalio and at specified intervals during treatment. Withhold and dose reduce or permanently discontinue Turalio based on severity of hepatotoxicity. Turalio is available only through a restricted program called the Turalio Risk Evaluation and Mitigation Strategy (REMS) Program.

    Clinical Trial Results

    The FDA approval of Turalio was based on ENLIVEN, a double-blind, randomized, placebo-controlled, global multi-center, pivotal phase 3 study which evaluated Turalio in patients with symptomatic TGCT for whom surgical removal of the tumor would be associated with potentially worsening functional limitation or severe morbidity. The first part of the study, the double-blind phase, enrolled 120 patients who were randomized (1:1) to receive either Turalio at 1000 mg/day for 2 weeks followed by 800 mg/day for 22 weeks or matching placebo, to evaluate the efficacy and safety of Turalio versus placebo. Study results showed the primary endpoint of tumor response rate by Response Evaluation Criteria v1.1 in Solid Tumors (RECIST) was 38% in Turalio-treated patients and zero percent for placebo-treated patients at Week 25. In addition, overall response rate by tumor volume score (TVS) was 56% in patients randomized to the Turalio and zero percent in patients randomized to the placebo arm at Week 25. Furthermore, the analysis of mean change from baseline in range of motion at Week 25 demonstrated a statistically significant improvement in patients treated with Turalio compared to placebo.

    Approval Date: 2019-08-01
    Company Name: Daiichi Sankyo
    Back to Listings

    Upcoming Events

    • 24May

      Powering an Effective Oversight Strategy with Clinical and Operational Insights

    • 25May

      2022 WCG Avoca Quality & Innovation Summit: Own the Future

    • 28Jun

      Effective Root Cause Analysis and CAPA Investigations for the Life Sciences

    • 16Oct

      WCG MAGI's Clinical Research Hybrid Conference - 2022 West

    Featured Products

    • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

      Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    • Surviving an FDA GCP Inspection

      Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

    Featured Stories

    • Protocol-360x240.png

      Avoid Deviations by Making Protocol Review a Team Effort

    • SelectionProcess-360x240.png

      Give Us a Voice: Sites Clamor for a Say on Vendor Selection

    • Convince-360x240.png

      Use Data and Details to Convince Site Leadership to Add Staff

    • AsktheExpertsBadge-360x240.png

      Ask the Experts: Listing Trial Staff and Others on the Statement of Investigator

    Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

    The information you need to adapt your monitoring plan to changing times.

    Learn More Here
    • About Us
    • Contact Us
    • Privacy Policy
    • Do Not Sell My Personal Information

    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 617.948.5100 – Toll free 866.219.3440

    Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing